CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

215110Orig1s000

Trade Name:	MAVYRET™ Oral Pellets, 50 mg/20 mg
Generic or Proper Name:	glecaprevir and pibrentasvir
Sponsor:	AbbVie Inc.
Approval Date:	June 10, 2021
Indication:	MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

CENTER FOR DRUG EVALUATION AND RESEARCH

215110Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	
Labeling	**X**
REMS	
Officer/Employee List	**X**
Multidiscipline Review(s) • **Summary Review** • **Clinical** • **Non-Clinical** • **Statistical** • **Clinical Pharmacology**	**X**
Product Quality Review(s)	**X**
Clinical Microbiology / Virology Review(s)	**X**
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

215110Orig1s000

APPROVAL LETTER

NDA 215110
NDA 209394/S-13

NDA APPROVAL
SUPPLEMENT APPROVAL
FULLFILLMENT OF POSTMARKETING REQUIREMENT

AbbVie, Inc.
Attention: Harshal Gupte, MS
Associate Director, Regulatory Affairs
Dept. PA72/Bldg. AP30-4
1 N. Waukegan Road
Chicago, IL 60024

Dear Ms. Gupte:

Please refer to your new drug application (NDA) and supplemental new drug application (sNDA) dated and received December 10, 2020 and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mavyret (glecaprevir and pibrentasvir), oral pellets and tablets.

These applications provide for the following:

- Safety and efficacy data from Study M16-123 Part 2 to support the use of Mavyret (glecaprevir and pibrentasvir) oral pellets for the treatment of pediatric patients 3 to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.

- To update the DOSAGE AND ADMINISTRATION section for use of oral pellets in pediatric patients 3 years of age and older.

- To update ADVERSE REACTIONS, USE IN SPECIFIC POPULATIONS, CLINICAL PHARMACOLOGY and CLINICAL STUDIES sections with data from Study M16-123 in pediatric patients 3 years of age to less than 12 years of age.

- To make corresponding changes to the Patient Information.

APPROVAL & LABELING

We have completed our review of these applications, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As.*[2]

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling and carton and container labeling submitted on May 19, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human*

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission "**Final Printed Carton and Container Labeling for approved NDA 215110**." Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Mavyret (glecaprevir and pibrentasvir), tablets and pellets shall be 24 months from the date of manufacture when stored at or below 30°C.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages from birth to less than 3 years of age because necessary studies are impossible or highly impracticable. This is because there is a high rate of spontaneous viral clearance and lack of significant disease progression in children less than 3 years of age, therefore, the number of patients requiring treatment is very small.

This product is appropriately labeled for use in pediatric patients 12 years and older or weighing at least 45 kg for this indication.

We note that you have fulfilled the pediatric study requirement for pediatric patients for ages 3 to less than 12 years old and weighing less than 45 kg with these applications.

FULFILLMENT OF POSTMARKETING REQUIREMENT

Your submission reported the final report for the following postmarketing requirement listed in the August 3, 2017 approval.

3246-1	Conduct a study to evaluate the pharmacokinetics, safety and treatment response (using sustained virologic response) of glecaprevir and pibrentasvir in pediatric subjects 3 through less than 18 years of age with chronic hepatitis C virus infection.	
	Study Completion:	07/2022
	Final Report Submission:	01/2023

We have reviewed your submission and conclude that the above requirement was fulfilled. This completes all of your postmarketing requirements acknowledged in our August 3, 2017 letter.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*[3]

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.[4] Information and Instructions for completing the form can be found at FDA.gov.[5]

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Myung-Joo Patricia Hong, Senior Regulatory Project Manager, at (301) 796-0807 or (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antivirals
Office of Infectious Diseases
Center for Drug Evaluation and Research

[3] For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
[4] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

ENCLOSURES:

- Content of Labeling
    - Prescribing Information
    - Patient Package Insert
    - Instructions for Use
- Carton and Container Labeling

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

POONAM MISHRA
06/10/2021 11:37:03 AM
For Division Director